

30 October 2025

Q1 ACTIVITIES REPORT 30 SEPTEMBER 2025**Highlights**

- Record quarterly revenue of \$14.1 million, a 210% increase on Q1 FY25 and a 47% increase on Q4 FY25.
- Substantial investment in cannabis flower procurement and working capital to meet European demand.
- Purchase orders from Germany A\$5.1m (A\$2.2m invoiced in Q1, with A\$2.9m to be invoiced in Q2) for the quarter with forecasted re-orders in Q3 FY26.
- Completed dual listing on Frankfurt Stock Exchange, ticker PR8.F
- Positive regulatory developments in Germany and United States.
- Cash on hand of \$4.5 million (excluding \$1.1m R&D refund for FY24).

Australian life sciences, pharmaceutical and consumer health products Company, **Bioxyne Limited (ASX:BXN)** ("Bioxyne" "Group" or the "Company") is pleased to report strong Q1 FY26 trading performance with revenue up 47% on the prior quarter and 210% on the prior year corresponding period.

To meet the significant demand from Europe the Company made a material investment in cannabis flower during the quarter with inventory on hand at ~A\$6.1m (up from \$3.6m in Q4 FY25). As a consequence, and together with an increase in other net working capital of A\$1.5m the Company returned an operating cash outflow of \$4.1m in the quarter, with cash receipts of A\$12.9m. Additional capex during the quarter was \$0.25m.

Trade receivables increased from \$2.4m in Q4 FY25 to \$6.0m in Q1 FY26, deferring cash receipts, because of extending payment terms to key clients that are increasing order volumes.

Total inventory increased from \$3.6m to \$6.1m from Q4 FY25 to Q1 FY26 as the business prepares to scale up its white label offering and cannabis flower revenues.

The Group's results were driven by Breathe Life Sciences (**BLS**) Australia, Australia's leading manufacturer and wholesaler of novel medicines, including cannabis, MDMA, and Psilocybin. Europe made a significant contribution with the first shipment to Adrex Pharma in Germany.

Commenting on the strong Quarter, Bioxyne's CEO, Sam Watson, stated: *"The first quarter of FY2026 has not only seen significant revenue growth but substantial developments in the business to build a platform for sustained growth going forward.*

These developments include quality control systems, additional physical infrastructure, new personnel, and engagement for UK and European expansion.

We remain excited with the opportunity and are executing on the strategy to deliver on previous guidance."

Revenue

Group revenue (Figure 1) attributable to significant outperformance from BLS Australia with its increased manufacturing capacity, with growth in white-label cannabis flower, pastilles, vapes and oils manufacturing. Europe delivered its first major sale of \$2.2m during the quarter to Farmakem/Adrex.

Figure 1 – BXN Group Revenue by Quarter (\$)





Figure 2 – Cash Receipts & Cash Generated From Operating Activities by Quarter (\$)



Cash Receipts

The Company generated cash receipts of \$12.95m during the quarter, representing a material increase on both the prior corresponding period of Q1 FY25 and the previous quarter.

Cash from operations was an outflow of \$4.1m in Q1 FY26 with further investment in inventory \$2.5m and other net working capital of \$1.5m to meet the growing trajectory of the business.

Internal management accounts are in line with the required run-rate to meet or exceed stated guidance of \$11.5m to \$13.5m Underlying EBITDA in FY26.

Operations

A further \$0.25 million in Capex during the quarter invested in security vaults and infrastructure to accommodate additional operations.

Working capital increased during the quarter to support business growth trajectory. The Company maintains a rigorous control of costs and working capital as the business expands.

The Company paid directors fees and salaries in the amount of \$181,250 for the Quarter.

Cash balance at the end of the Quarter was \$4.5m. This excludes \$1.1m to be received shortly in respect of a research and development tax offset refund.

Dual Listing on Frankfurt Stock Exchange

The Company successfully listed on the Frankfurt Stock Exchange (**FSE**) on 13 October 2025 trading under the ticker code PR8.F

The listing supports the Company's focus on Europe, with Germany the largest and fastest growing legal cannabis market in Europe projected to surpass €1 billion (A\$1.8 billion) in sales by 2026.

Regulatory Developments

Potential rescheduling of Cannabis in the U.S from Schedule 1 to Schedule III could facilitate broader research access, ease banking and tax constraints, and unlock pathways for institutional investment in cannabinoid therapeutics. Bioxyne is well positioned to capitalise on easing regulations.

German regulations in relation to patient access and delivery systems should also benefit the Company given the established relationship with Farmakem and Adrex.

Outlook

The Company is focussed on:

- Improving processes, including ERP systems, to manage the growing business in Australia, UK and EU.
- Planning and execution of manufacturing/distribution facilities in UK and Europe to meet growing demand;
- Achieving the FY26 revenue guidance of \$65m - \$75m;
- Achieving the FY26 EBITDA guidance of \$11.5m - \$13.5m;
- Gaining EU GMP certification in Czechia for distribution to European markets; and
- Scaling its medicinal cannabis product sales in the UK and European markets with local partners.



The quarterly activities report has been approved for release by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com



About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow. Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- c) White label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- d) Research and development for third party customers; and
- e) Direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson®

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>;

International: <https://breathelifesciences.com>

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bioxyne Limited

ABN

97 084 464 193

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	12,949	12,949
1.2 Payments for		
(a) research and development	(40)	(40)
(b) product manufacturing and operating costs	(15,119)	(15,119)
(c) advertising and marketing	(63)	(63)
(d) leased assets	(27)	(27)
(e) staff costs (including directors fees)	(547)	(369)
(f) administration and corporate costs	(1,246)	(1,246)
1.3 Dividends received (see note 3)		
1.4 Interest received	32	32
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(4,061)	(4,061)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(245)	(245)
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material) cash on acquisition of subsidiary		
2.6	Net cash from / (used in) investing activities	(245)	(245)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings (lease)/other	1,213	1,213
3.6	Loan to third party		
3.7	Repayment of borrowings		
3.8	Dividends paid		
3.9	Other	(15)	(15)
3.10	Net cash from / (used in) financing activities	1,198	1,198

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	7,668	7,668
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,061)	(4,061)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(245)	9245)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,198	1,198
4.5	Effect of movement in exchange rates on cash held	(17)	(17)
4.6	Cash and cash equivalents at end of period	4,543	4,543

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,543	5,668
5.2	Call deposits	-	2,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,543	7,668

**6. Payments to related parties of the entity and their
associates**

6.1 Aggregate amount of payments to related parties and their
associates included in item 1

6.2 Aggregate amount of payments to related parties and their
associates included in item 2

**Current quarter
\$A'000**

181

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments

The amount in item 6.1 represents director's fees and salaries.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(4,061)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	4,543
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	4,543
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	1.2

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6

If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

No. Investment in inventory and receivables will be converted to cash in the next quarter. The business is growing rapidly and the investment in working capital in this quarter has been necessary to secure product for contracted supply to Europe, UK and Australia.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

No. The Company monitors cash requirements on a rolling 6 week and 3 monthly basis, and while it has the ability to raise capital, forward forecasts indicate that this is not necessary. In addition the Company will receive an R&D tax offset of \$1.1m in the next quarter.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Yes, the business cash flow projections indicate that it will have sufficient internally generated cash resources to enable the business to execute on its business plan and continue on its growth trajectory.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2025.....

Authorised by: ..The Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.